Alumis prices $300M upsized public offering
Source: SeekingAlpha
2026-01-08 02:01:04 ET
More on Alumis
- Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise
- Alumis surges on late-stage trial win for lead drug in plaque psoriasis
- Seeking Alpha’s Quant Rating on Alumis
- Historical earnings data for Alumis
- Financial information for Alumis
Read the full article on Seeking Alpha
For further details see:
Alumis prices $300M upsized public offering
Alumis Inc.
NASDAQ: ALMS
ALMS Trading
2.23% G/L:
$29.295 Last:
342,725 Volume:
$29.72 Open:
ALMS Latest News
ALMS Stock Data
$2,775,820,586
61,905,288
10.13%
33
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
